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Abstract 
Objectives 
This study set out to describe the progression of hearing loss in patients with Neurofibromatosis 
type 2 (NF2), treated in a quaternary multidisciplinary clinic. It also aimed to compare hearing loss 
across patients grouped according to a known genetic severity score to explore its utility  for 
prognostication.  
Methods 
We conducted a retrospective cohort study of 147 patients with confirmed NF2 diagnosis for a 
mean observational period of 10 years. Pure tone audiometry (PTA), optimum discriminations scores 
(ODS), and genotype data were collected. Patients were classified according to hearing class 
(American Academy of Otolaryngology), their candidacy for auditory implantation (UK National NF2 
consensus) and grouped by genetic severity as :1. Tissue mosaic, 2A. Mild Classic, 2B. Moderate 
Classic and 3. Severe.  Survival analysis investigated the effect of genetic severity on the age of loss 
of serviceable hearing. 
Results 
Genetic severity was a significant predictor of hearing outcomes such as ODS, hearing classification 
and maximum annual PTA deterioration. Whilst the overall median age of loss of serviceable hearing 
was 78 years, there was significant variation according to the genetic severity (median for severe 
patients was 32 years compared to a median of 80 for tissue mosaic patients). 
Conclusion 
This is the first description of long term hearing outcomes in a clinical setting across a large 
heterogeneous cohort of patients with NF2.   The results highlight the potential importance and 
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benefit of considering the genetic severity score of patients when undertaking treatment decisions, 
as well as planning future natural history studies. 
 
Level of evidence: 2C 
Keywords: 
Neurofibromatosis 2, genetic severity, natural history, hearing loss, acoustic neuroma, vestibular 
schwannoma 
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Introduction 
Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder with a prevalence of 1 in 
60,000
1
, which is characterised by the development of multiple benign tumours of the central and 
peripheral nervous system, polyneuropathy, as well as cutaneous and ocular abnormalities. Bilateral 
vestibular schwannomas (VS) are the hallmark of NF2 occurring in over 95% of NF2 patients and 
gradual VS growth or interventions for their treatment can lead to significant hearing loss, which is 
often bilateral and profound 
2
. Since hearing loss significantly impacts on the quality of life for 
patients with NF2
3-5
 hearing preservation is a key aim when considering patient management 
decisions. Despite this, increasing tumour burden may necessitate treatment interventions at the 
cost of hearing
2
. In patients with NF2 whose vestibular schwannomas are conservatively managed, 
hearing loss is usually gradual although sudden sensorineural hearing loss has also been observed
6-9
. 
Coupled to hearing loss, frequent concomitant poor vision further exacerbates communication 
issues and highlights the need for a multidisciplinary approach for optimal patient management 
10,11
.  
Improved understanding of the course of hearing loss in patients with NF2 would enhance 
prognostication and consequently help to inform management decisions as well as contribute to 
patient education. There are only a limited number of studies dedicated to the progress of hearing 
loss in NF2
7,12-14
 or the underlying mechanism
15-17
 and despite the abundance of natural history 
studies delineating hearing loss secondary to sporadic VS
9,18-21
, the VS growth rates reported are 
highly variable and not generalisable to NF2. In addition, the rate of hearing loss in NF2 does not 
consistently correlate with radiological data measuring VS growth
22
.  Studies of conservatively 
managed tumours in NF2
13
 report on more mildly affected cohorts with the mean growth rates of 
conservatively managed VS being significantly slower when compared to growth rates of VS that are 
excised
2,23
. Other potential methodological issues in previous longitudinal studies relate to relatively 
short follow-up times
7
 and the eligibility criteria of patients biasing towards certain age ranges
23-25
.  
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Another confounding factor in natural history studies in NF2 is that there is great variance in the 
clinical presentation and disease progression for patients, possibly stemming from the type and 
location of the mutation in the NF2 gene or potential mosaicism
26-29
. These methodological 
limitations potentially reduce the practical clinical applicability for patients who desire to be 
informed about the probability of and timescale to hearing loss.  
Recently, a genetic severity score was found to reliably predict phenotype for NF2 patients in 
several dimensions of morbidity such as hearing, ocular findings, tumour load and burden of 
interventions 
30
.  It would therefore be highly instructive to stratify the risk of hearing loss according 
to genetic severity. This study sets out to describe the first large scale observational study of the 
progression of hearing loss as experienced for more than a decade by NF2 patients managed in a 
multi-disciplinary centre and to examine potential differences arising as a consequence of the 
patients’ genetic severity
30
. The primary aim was to describe the rate of hearing loss and age at loss 
of serviceable hearing for patients with NF2 regardless of treatment intervention, stratifying 
according to genetic severity. Such data could then potentially be used to help newly diagnosed 
patients and their clinicians further understand the individual’s likely rate of hearing loss and 
therefore facilitate more informed decisions on treatment options. 
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Materials and Methods 
We undertook a retrospective anonymized cohort study by reviewing routinely recorded patient 
information held in the departmental database to extract demographics, genetic severity and 
hearing data for all patients managed within the South West of England National NF2 Service.   All 
eligible patients had a confirmed diagnosis of NF2
31-34
 and were classified using a genetic severity 
score
30
.  All patients were included regardless of whether they were treatment naive, had 
undergone surgery, radiotherapy, bevacizumab or a combination of treatment modalities. 
The primary outcome measure for hearing was optimum speech discrimination score(ODS) in 
the better hearing ear.  This was determined using Arthur-Boothroyd word lists presented in 
optimum aided conditions.  In patients with <50% ODS, Bamford-Kowal-Bench(BKB) sentence 
testing scores were also recorded in order to assess their candidacy for auditory implantation
35
.ODS 
assessments were offered to all patients annually or more frequently since the start of the NF2 
national service in 2010, with a few exceptions: patients who lost their serviceable hearing prior to 
2010, as well patients who were non-testable due to either learning difficulties, insufficient English 
language or young age
10
. In addition, pure tone average (PTA) was used as a secondary outcome 
measure given its widespread availability, especially for patients managed prior to 2010.  A PTA  was 
calculated for each ear using the thresholds at 500, 1000, 2000, 4000 Hz
36
.   The rate of hearing loss 
was calculated per ear by dividing the PTA change from baseline to last review by the period of 
observation. All left ears and right ears were analysed separately as they were considered to be both 
biologically and statistically independent.  Young children with PTA within the normal hearing range 
(≤20 dB)
37
were assumed to have ODS of 100%. All audiological assessments were carried out 
according to the British Society of Audiology guidelines by fully qualified audiologists in a sound-
insulated room. 
Patients hearing was classified using two different systems applied to their better hearing ear 
(table 1):Firstly, we used the American Association of Otolaryngology-Head and Neck Surgery(AAO-
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HNS) scheme
38
 in order to allow for direct comparison with previous studies, and secondly, we 
applied the UK national NF2 consensus grading
35
, which is routinely used in the UK in this setting to 
assess hearing loss and auditory brainstem and cochlear implantation candidacy.   
This study’s primary aim was to determine the age of loss of useful hearing in patients with NF2 
in order to provide the most clinically relevant information that may be of use in management 
decisions. Loss of serviceable hearing was defined as AAO-HNS classes C or D or, in the case of some 
patients who lost their hearing prior to 2010, a detailed case note review was undertaken using a 
pragmatic definition of the year in which it was recorded they were no longer able to derive 
significant benefit from hearing aids in terms of speech understanding. Concomitantly with 
investigating survival to loss of hearing, we undertook a survival analysis defining the end point as a 
score of <50% ODS, corresponding to Grade 3 or worse on NF2 consensus grading system(AAO-HNS 
class D rather than C & D). This is the threshold where patients would be referred for more detailed 
hearing assessment with sentence score testing and potentially considered for auditory 
implantation.  
 Statistical analysis: 
SPSS 23 was used for all statistical analyses. Genetic severity and hearing classifications were 
treated as ordinal variables. We reported standard summary statistics with the statistical 
significance of inferences set to 5%.Associations between variables, and where necessary controlling 
for possible confounders, were investigated using Spearman's correlations, and where appropriate 
partial Spearman’s correlations, after visually confirming monotonic relationships of the variables 
using scatterplots.T-tests were used for pairwise comparisons; inspection of outliers in the pairwise 
differences revealed they were not extreme and did not unduly influence the results and they were 
therefore kept in the analysis. Trends in the proportion of patients in each hearing classification 
associated with genetic severity were investigated using Mantel-Haenszel linear-by-linear χ
2
 tests of 
association. The agreement of the two hearing classification systems was investigated using 
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Goodman and Kruskal's γ and we reported the population value G. Kaplan-Meier survival analysis
39
 
was conducted to examine if genetic severity had a significant impact to the age of loss of 
serviceable hearing and to produce survival probabilities and hazard rates. A similar percentage of 
censored cases were present in the four different genetic severity groups and the pattern of 
censoring was similar. 
Results 
One hundred and forty seven patients met the inclusion criteria after excluding one patient with 
congenital hearing loss. The mean observational period was 10 years(SD=8) and the mean age of 
patients at their latest follow-up was 43.5 years(SD=19.3). The dates of diagnoses of NF2 ranged 
from 1969 to 2016. The breakdown of the study’s patient population by genetic severity score is 
recorded in table 2 along with their age and the total period of observation. As expected, patients 
were followed-up at a significantly younger age when they had a severe phenotype compared with 
tissue mosaic(p=5.3x10
-22
) but there was no overall difference in the duration of follow-up amongst 
the different genetic severity groups(p=.17). 
There were 137 patients for whom we had ODS  recorded at the latest review and we compared 
their relative hearing by focusing on their better hearing ear and stratifying across different genetic 
severity groups. Whilst the mean maximum ODS was 72.08% (95%CI=65.49, 78.67) across all 
patients, there was significant variability depending on the genotype of the patients(p=.01). In 
particular, table 3 shows that the mean maximum ODS for patients in the tissue mosaic group was 
85.84%(95%CI=78.91, 92.76), whereas severe-genotype patients had an average maximum ODS that 
was significantly lower and with a greater variation (Mean=55.94%,95%CI=32.23, 79.65%). 
Pure Tone Average results(PTA) were available for 70 right and 69 left ears(Appendix 1). The 
mean follow-up period from baseline PTA to last review for the 81 patients for whom we had 
audiograms at both points was 82 months(SD=47). There was a statistically significant worsening in 
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the mean PTA from baseline to last review of 14.14 dB and 15.07 dB for right(p=.000008) and 
left(p=.000058) ears respectively. The total magnitude of deterioration in hearing was related to the 
total period of observation for both right(p=.000019) and left ears(p=.006). Patients who presented 
at older age had worse hearing at baseline(right ear:p=.006, left ear:p=0.000376) but a less severe 
phenotype(p=1.31x10
-12
).After controlling for age, patients with more severe genotype were found 
to have worse pure tone thresholds at presentation(right ear:p=.009,left ear:p=1.55x10
-7
). 
We examined the rate of hearing loss of NF2 patients and observed that the maximum rate of 
yearly PTA deterioration varied significantly for patients in different genetic severity 
categories(p=.02).Notably from table 4, PTA averages for patients in the severe group could 
deteriorate by 15.9dB per year in their most frangible ear; a decline which is more than four times 
greater the maximum rate of deterioration of tissue mosaic patients(2.6dB/annum). 
The genetic severity of NF2 patients was found to be a significant predictor of their hearing 
classification. In particular, using data from their latest review, we classified 95 patients using the 
AAO-HNS class and 143 patients using the UK national NF2 consensus system, and found that there 
were significant trends between increasing genetic severity and the proportions of patients in worse 
classes of AAO-HNS(p=.007) as well in worse hearing grades(p=.001)(Figure 1). For example, more 
than half (57.1%) of the patients in the severe group were found to be without serviceable 
hearing(Classes C and D) and only 35% of them were in Class A, compared to 64% of patients in the 
tissue mosaic group who were classified as Class A and less than 26% of whom were without 
serviceable hearing. Comparably, the genetic severity of patients also dictated their UK NF2 hearing 
grade classification well; notably with the percentage of patients in grade 6 rising from 3% in the 
tissue mosaic group to 22% in the severe group. Unsurprisingly, the two hearing classifications were 
very strongly associated(G=.998 ,p=1.24x10
-22
) and described the patients in this study in a similar 
fashion although there were thirteen patients who would be classified as having serviceable hearing 
using the UK national NF2 consensus but were in Classes C or D using AAO-HNS(Appendix 2). 
Page 9 of 25
John Wiley & Sons
The Laryngoscope
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
In the clinical management of NF2 patients, being able to predict the age of hearing loss would 
be of great benefit when making treatment decisions. The age of loss of serviceable hearing was 
considered to be the most important end point with regards to hearing impairment. A survival 
analysis was performed to determine the age of loss of serviceable hearing (AAO-HNS classes C or D) 
in our NF2 cohort  and whether it differed between genetic severity groups. Figure 2 illustrates the 
survival functions for the patients in each genetic severity group. Genetic severity was a significant 
overall predictor of age of loss of useful hearing as determined by a log rank test which revealed that 
the survival distributions for the four groups were statistically significantly 
different,χ
2
(3)=46.25,p=5.03x10
-10
.  
We then set out to do pairwise comparisons in order to determine which of the genetic severity 
groups differed from each other in terms of age of loss of serviceable hearing and found that there 
was a statistically significant difference in the survival distributions between all group-pairs except 
when comparing the survival of 2A and 2B, an effect clearly illustrated in figure 1. The mean survival 
times and medians(the age at which 50% of patients in a group still maintained serviceable hearing 
in at least one ear) were recorded in table 5. From table 5 it is apparent that there are marked 
differences in the ages of loss of serviceable hearing for NF2 patients of varying genotype. 
Remarkably, in routine clinical practice we observed that whilst 50% of patients in the tissue mosaic 
group preserve their hearing until 80 years of age, this threshold rapidly drops to 44-46 years for 
mild and moderate classic patients and to only 32 years for patients in the severe group.  We further 
validated the above data using the UK national NF2 consensus grade determination of auditory 
implant candidacy and found that the results replicated the aforementioned findings. 
Discussion 
This is the first study to have long-term follow up from a heterogeneous cohort of patients 
managed within a specialised multidisciplinary NF2 service and provides a ‘real world’ overview of 
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hearing loss including  loss due to necessary treatment intervention (not just conservatively/non-
operatively managed patients). The aim was to provide data that would apprise patients and their 
clinicians of their likely progression to loss of hearing so as to better inform treatment decisions 
relating to the management of their VS as well as to advise future specialised service configurations 
and healthcare planning.  A known genetic severity score was used to stratify patients to provide 
more accurate individualised information
30
. 
Our findings clearly demonstrate the importance of accounting for the genetic severity of patients in 
delineating the course of hearing loss in NF2. The type of NF2 mutation underlies phenotypic 
severity of disease such as VS tumour doubling times, which can in turn affect time to loss of useful 
hearing
25
. The use of a genetic severity score provides a more in depth understanding of the 
variation in the progression of hearing loss amongst a heterogeneous cohort. Notably,  we observed 
that overall, across all genetic severity groups, 50% of patients with NF2 appear to retain useful 
hearing up to the age of 78; this finding however is not very informative for patients who are severe, 
half of whom may lose serviceable hearing before 32 years, almost 50 years before milder tissue 
mosaic patients. Our results demonstrate significant differences in age of loss of useful hearing 
depending on genetic severity; the implications of this are that a patient with a new diagnosis of VS 
with a mild genetic severity may be reassured that it is likely they ill preserve serviceable hearing 
for an extended period of time.  In contrast, a patient with vestibular schwannomas and a severe 
mutation may be counselled towards earlier intervention that might secure hearing rehabilitation in 
the long term.  This may include early SRS with or without subsequent cochlear implantation
40
, early 
VS resection with cochlear nerve preservation and cochlear implant insertion
41
 , or excision with 
auditory brainstem implant insertion (including sleeper). 
The genetic severity correlated well with ODS, AAO-HNS class and UK NF2 consensus hearing grades 
as well as annual PTA deterioration of the most frangible ear. As our results stem from a 
heterogeneous cohort they are not directly comparable to other reported cohorts however the 
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overall deterioration in PTA reported herein is within the range reported for conservatively managed 
patients in NF2
13
. Whilst the deterioration of the most frangible ear is variable depending on genetic 
severity, the rates reported for milder cohorts who are likely to be more conservatively managed, 
are also in agreement with previous findings (0-9.6dB/year). The increased rate of PTA deterioration 
in severe patients likely relates to increased clinical severity and disease burden specifically 
vestibular schwannoma (and other CPA) and their growth behaviour or the treatments required for 
these and other NF2 tumours. 
Genetic severity score is known to correlate with disease burden and the need for treatment 
intervention (both of which contribute to hearing loss) 
30
. Genetic severity score alone was therefore 
used to stratify patients disease severity.  A further reason for this is that genetic severity can be 
determined at diagnosis (including pre-symptomatic) and is therefore more useful for aiding future 
prognostication. 
Whilst there was a clear difference in the ages of loss useful hearing between group 1 and 2, and 
between 2 and 3, group 2A and 2B  patients are the most similar. This might be because our 2A 
cohort had relatively few mild missence mutations, which may have resulted in an inability to 
demonstrate a significant difference the median ages to loss of useful hearing between 2A and 2B.  
An important limitation of the current observational retrospective cohort study arises from recall 
bias or inaccuracies in using historical data for determining age at loss of useful hearing in those 
patients in whom it occurred prior to 2010. Moreover, whilst more widely available, PTA is not as 
useful in assessing hearing in NF2 as ODS
10
  and dB rate of loss of hearing may not be helpful to 
patients. Furthermore, changes in treatment in recent years such the introduction of bevacizumab 
which may better preserve hearing compared with other modalities
2
, may mean that historical data 
may not be accurate when applied to newly diagnosed patients being offered currently available 
treatment regimes.  It should be noted that all patients were included in this study regardless of 
whether they had undergone treatment intervention  Whilst there is clear benefit in a natural 
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history study of only treatment naïve patients, this would result in exclusion of patients with more 
severe disease who inevitably require treatment as a young adult.  Previous studies have therefore 
been limited to milder cohorts.  Our aim was to include all NF2 patients in our large clinic regardless 
of whether their hearing loss was due to treatment naïve tumours or secondary to treatment 
interventions that were deemed necessary for tumour control (e.g. decompression of 
brainstem).  We acknowledge that there are variations in management philosophy for units treating 
patients with NF2 which may limit the direct usability of the median age to loss of 
hearing.  However, importantly the study does highlight the benefit of using a genetic severity 
scoring system to help inform and counsel all patients not only mild ones. Centres with significantly 
different management strategies could undertake a similar review of their cohort to determine time 
to loss of hearing for each genetic severity as achieved by their own individual management 
practices to give more accurate unit specific data.  Publication of similar studies such as ours using 
the genetic scoring system would allow for more direct comparison of time to loss of hearing and 
how this may vary according to management philosophy.  
Overall, the main strength of the current work is that it provides a starting point for the use of 
genetic severity scoring as a clinical tool to help predict likely rates of hearing loss and enhance 
individualised patient counselling.  Further work should consider extending this work prospectively 
using primarily ODS to determine end points of hearing survival analyses.  In addition this could form 
part of the development of a predictive model following further investigation of other potential 
predictors of hearing loss such as tumour size and growth rate.   
Conclusion 
This is the first description of long-term hearing outcomes in a clinical setting across a large 
heterogeneous cohort of patients with NF2 managed using all treatment modalities within a 
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specialised quaternary MDT.   Stratifying patients according to genetic severity allows for more 
informed prognostication of the likely timescale for hearing deterioration.  This information may be 
useful to both patients and clinicians when making complex treatment decisions.   
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Tables 
 Table 1: Classification of patients’ hearing accorring to the American Association of Otolaryngology-Head and Neck 
Surgery (AAO-HNS) scheme and the UK national NF2 consensus grading, 
American Association of 
Otolaryngology-Head and Neck Surgery 
  
Ear serviceability UK national NF2 consensus for 
auditory brainstem and cochlear 
implantation 
 
Class Definition Grade Definition 
A †ODS: 71 -100% 
‡PTA: ≤30 dB 
 Serviceable hearing 
  
1 ODS: 70 -100% 
 
 
B 
 
ODS: 50 -100% 
PTA: 31-50 dB 
2 
  
ODS: 50 – 69 % 
3 ODS: 0-49% 
 §BKB: 50-100% 
C ODS: 50 -100% 
PTA > 50 dB 
Non serviceable 
hearing 
   
  
4 ODS: 0-49% 
 BKB: 0-49% 
 
D ODS: 0-49%  5 Auditory implant 
 
  
 
6 
 
Dead ears 
†ODS: Op]mum Discrimina]on Score, ‡PTA: Pure Tone Average, §BKB: Bamford-Kowal-Bench 
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Table 2: Cohort descriptives by genetic severity 
Genetic Severity 
Patients Age at latest follow-up 
(years) 
Total observation 
period (years) 
N % Mean SD Mean SD 
1. Tissue Mosaic 66 44.9% 57.58 14.42 10 9 
2A. Mild Classic 30 20.4% 36.38 12.81 10 9 
2B. Moderate Classic 32 21.8% 33.39 15.99 9 7 
3. Severe 19 12.9% 23.84 12.45 7 7 
Total 147 100.0% 43.51 19.29 10 8 
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Table 3: Optimum speech discrimination score in the better hearing ear (%)  
Genetic Severity 
Optimum speech discrimination score 
better hearing ear (%) 
Mean SD 
1. Tissue Mosaic 85.84 27.27 
2A. Mild Classic 57.96 44.56 
2B. Moderate Classic 65.47 42.20 
3. Severe 55.94 46.12 
Total 72.08 39.01 
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Table 4: Maximum Pure Tone Average (PTA) (dB/year) rate by genetic severity 
Genetic Severity 
Maximum PTA rate 
(dB/year)   
Mean SD 
1. Tissue Mosaic 2.87 5.28 
2A. Mild Classic 4.65 4.95 
2B. Moderate Classic 8.23 12.20 
3. Severe 13.54 29.40 
Total 6.04 13.74 
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Table 5: Mean and Median ages of survival to loss of serviceable hearing (AAO-HNS Class C or D) by genetic severity 
 
  
Genetic severity Mean Std. Error 
95% Confidence 
Interval limits 
Median Std. Error 
95% Confidence 
Interval limits 
Lower Upper Lower Upper 
1. Tissue Mosaic 75.76 2.10 71.65 79.87 80.00 1.73 76.60 83.40 
2A. Mild Classic 44.25 3.38 37.61 50.88 44.00 4.05 36.07 51.93 
2B. Moderate Classic 54.99 7.95 39.40 70.58 46.00 4.55 37.08 54.92 
3. Severe 33.20 5.67 22.08 44.32 32.00 6.75 18.77 45.23 
Overall 66.58 2.95 60.81 72.35 78.00 5.80 66.63 89.37 
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Figure legends 
Figure 1: Apportionment of patients in each genetic severity group by each hearing classification: AAO-HNS: 
American Association of Otolaryngology-Head and Neck Surgery, UK hearing grades: UK national NF2 consensus for 
auditory brainstem and cochlear implantation. 
Figure 2: Plot of the Kaplan-Meier survival function curves for each genetic severity group against age 
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Appendix legends 
Appendix 1: Pure Tone Average (PTA) at baseline and last review for 82 patients for right (PTA-R) ears and left (PTA-
L) ears 
  
Appendix 2: Crosstabulation of classifications of patients with NF2 according to two systems: American Academy of 
Otolaryngology - Head and Neck surgery and UK national NF2 consensus t Hearing Grade 
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Figure 1: Apportionment of patients in each genetic severity group by each hearing classification: AAO-HNS: 
American Association of Otolaryngology-Head and Neck Surgery, UK hearing grades: UK national NF2 
consensus for auditory brainstem and cochlear implantation.  
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Figure 2: Plot of the Kaplan-Meier survival function curves for each genetic severity group against age  
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